MitoQ for Fatigue in Multiple Sclerosis (MS)

Last updated: April 3, 2025
Sponsor: VA Office of Research and Development
Overall Status: Active - Not Recruiting

Phase

1/2

Condition

Multiple Sclerosis

Neurologic Disorders

Pain (Pediatric)

Treatment

40mg of MitoQ

Placebo

20 mg MitoQ

Clinical Study ID

NCT04267926
NURB-022-19S
4337
  • Ages 18-70
  • All Genders

Study Summary

The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • MS (any clinical subtype) as diagnosed by the 2017 McDonald criteria

  • EDSS score of 2 to 8

  • complaint of fatigue that has been persistent for at least two months

  • Modified Fatigue Impact Scale (MFIS) score of 38 or greater

Exclusion

Exclusion Criteria:

  • treatment with systemic glucocorticoids in the prior six weeks

  • Beck Depression Inventory (BDI) >31 or BDI-FS>10 (severe depression)

  • significant MS exacerbation in prior 30 days

  • previous use of MitoQ or Coenzyme Q10 (CoQ10) within thirty days of screeningappointment

  • other significant health problem that might increase risk of patient experiencingAdverse Events (AEs), e.g.:

  • active coronary heart disease

  • liver disease

  • pulmonary disease

  • diabetes mellitus

  • pregnancy or intending to become pregnant or breastfeeding

  • unable to complete the self-report forms

  • unable to give informed consent

  • prisoners

  • any condition which would make the patient in the opinion of the investigatorunsuitable for the study

Study Design

Total Participants: 47
Treatment Group(s): 3
Primary Treatment: 40mg of MitoQ
Phase: 1/2
Study Start date:
April 01, 2020
Estimated Completion Date:
March 31, 2026

Study Description

Recruitment of subjects on hold due to COVID-19 pandemic

MitoQ is a potent antioxidant dietary supplement with potentially significant immunomodulatory and anti-inflammatory properties. While the cause of MS related fatigue is uncertain, the investigators believe that mitochondria dysfunction and resultant neuronal energy depletion may be an important contributor to fatigue in MS.

This clinical trial will evaluate the potential beneficial effects of MitoQ on MS fatigue. It will also explore the effects of MitoQ on cognitive function, quality of life and mood. If enrolled in the study, patients will take two capsules of the study drug or placebo at the same time every day for twelve weeks. There will be 4 study visits where the participant will undergo medical and nervous system examinations, questionnaires, and blood draws. Because it is a placebo-controlled trial, participants will have a 33% chance of receiving either placebo (inactive), 20mg of MitoQ, or 40mg of MitoQ. This will be a blinded randomized study, meaning neither the participant nor the investigator will know who received the placebo or study drug.

Connect with a study center

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon 97207-2964
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.